C4 Therapeutics, Inc. (CCCC) News
Track canonical SquawkNews coverage tagged to CCCC, C4 Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 6 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
C4 Therapeutics presents Phase 1 biomarker gains for cemsidomide; 75 µg combo dose with elranatamab declared safe
C4 Therapeutics reported new biomarker data showing T—cell activation from the cemsidomide Phase 1 trial and supportive preliminary Phase 1b data with elranatamab; the 75 µg combination dose was declared safe and the Pha
NEWS | Sep 25, 2026, 11:14 AM UTC
L
C4 Therapeutics, Inc. (CCCC) Reports Early Biomarker and Safety Updates in Cemsidomide Combos
C4 Therapeutics presented biomarker data showing T—cell activation with cemsidomide and said the 75 µg dose with elranatamab was declared safe, enabling expansion at 75 µg and escalation to 100 µg; full Phase 1b cohort d
NEWS | Sep 25, 2026, 11:01 AM UTC
L
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
Immunomodulatory Effects of Cemsidomide with Dexamethasone from Phase 1 Trial Demonstrated Robust T-cell Activation, a Key Component of Cemsidomide’s Dual Mechanism of ActionBiomarker Data from First Two Patients in Phas
NEWS | Sep 25, 2026, 11:01 AM UTC
L
C4 Therapeutics to present new biomarker data for cemsidomide plus dexamethasone
C4 Therapeutics said it will present new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd IMS Annual
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
C4 Therapeutics to present biomarker data on cemsidomide plus dexamethasone
C4 Therapeutics said it will present new biomarker data on cemsidomide’s immunomodulatory effects with dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial at IMS.
EQUITY | Sep 03, 2026, 11:00 AM UTC
L
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Creative Medical Tech (NASDAQ: CELZ ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings (Cayman) (NASDAQ: C
EQUITY | Jun 30, 2026, 05:05 PM UTC